Skip to main content

CV Event Prediction, Risk Assessment in Type 2 Diabetes

Provider Medical Team Looking at Xray

Investigators have found that using a Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS 2°P) is a reliable predictor of cardiovascular events in patients with type 2 diabetes. In the randomized clinical trial, SAVOR-TIMI 53, of more than 16,000 patients randomly assigned to receive either saxagliptin or matched placebo, researchers found the use of TRS 2°P demonstrated a strong risk gradient for the primary end point (CV-related death, myocardial infarction, or ischemic stroke) in the patient population. Identifying patients at risk for atherothrombotic events with the TRS 2°P is “essential as clinicians and patients balance the competing considerations of treatment benefit, cost, and complexity in a field of expanding therapies,” according to investigators. Read more about the study at Endocrinology Advisor.